alexa The Challenge Of Genetic Diversity In Clinical Trials: Is Precision Medicine Up To The Challenge?
ISSN: 2161-1025

Translational Medicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

2nd International Conference on Translational & Personalized Medicine
August 05-07, 2013 Holiday Inn Chicago-North Shore, IL, USA

Paul A. Frohna
ScientificTracks Abstracts: Transl Med
DOI: 10.4172/2161-1025.S1.008
Abstract
Precision Medicine is a drug development paradigm that has evolved within oncology where cancer-causing genetic mutations have been known or suspected for some time, and where the toxicity and poor efficacy of non-specific chemotherapeutics promoted the search for targeted, less toxic therapies against these mutations. While programs like trastuzumab for HER-2 over-expression in breast cancer, crizotinib for ALK fusion proteins in NSCLC, and vemurafinib for BRAF V600E mutations in melanoma are shining success stories for Precision Medicine, there are surprisingly few others. It has become very apparent that despite the application of Precision Medicine the response rates in oncology clinical trials have not approached 100% or even come close. The leading hypothesis is that intra-tumor genetic diversity of distinct subpopulations of cells is the key driver for resistance and the disappointing results with targeted therapies. The recent tumor sequencing work to date suggests that how, when and where tumor samples are collected and analyzed need to be thoughtfully planned and implemented in clinical trials in order to maximize the utility of this genetic diversity information for patient selection criteria or for post-hoc subgroup analysis. While oncology has been the original playground for Precision Medicine, examples of other diseases/therapeutic areas where these patient selection criteria are likely to be very beneficial in improving the successes of clinical trials will also be briefly discussed. The future of Precision Medicine is promising, and if implemented carefully and consistently should improve clinical trial success rates and deliver more effective treatments for physicians and patients.
Biography
Paul A. Frohna has a Ph.D. in Pharmacology from the University of Pennsylvania and an M.D. (Internal Medicine) from Georgetown University in Washington, DC. He has been conducting translational research in the biotech industry for more than 14 yrs having served in roles from Medical Director to Chief Medical Officer at companies like Genentech, CV Therapeutics, Fibrogen and ProFibrix. He is currently the CMO at ProFibrix, Inc. and an industry consultant providing services in translational medicine, clinical pharmacology, and clinical trial design. He has designed clinical programs in regenerative medicine, hematology, oncology, immunology, neurology and cardiology.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version